Dr Belamy-Bin Cheung

Tabs

Main

Contact Category:

Conjoint

Discipline:

Paediatrics

Dr Belamy Cheung, BMed, MSc, PhD

Deputy Leader and Manager of Molecular Carcinogenesis Program
Children’s Cancer Institute Australia
Lowy Cancer Research Centre, University of NSW
PhD Student Supervisor and Senior Lecturer (UNSW)
Visiting Professor, The School of Life Sciences Technology, Tongji University Shanghai, China
Adjunct Professor, Academy of Medical Sciences, Zhengzhou University, China

Dr Belamy Cheung graduated from Sun Yat-Sen University of Medical Science Guangzhou, China in 1983, and obtained her Master and PhD degrees at the Faculty of Medicine, UNSW Sydney in 1994 and 2004, respectively. Now she is the Deputy Leader and Manager of the Molecular Carcinogenesis (MC) Program at Children's Cancer Institute Australia. Dr Cheung has published 46 original or review articles on the top-ranked journals including Nature Reviews Cancer, Science Translational Medicine, Oncogene and Journal of the National Cancer Institute. She attracted 1420 citations, h-index 18 (Scopus). She has also demonstrated a strong commitment to research supervision and mentoring. Since 2004, she has supervised/mentored more than 40 research assistants, undergraduates, PhD students and Postdocs. Dr Cheung directs and drives the research in all 3 themes in the MC Program: developing inhibitors for MYC oncoproteins, identification of co-factors for MYCN oncoprotein, and, establishing novel combination therapies of epigenetic drugs for cancer treatment. Dr Cheung is the Vice-President of the Australian Association for Chinese Biomedical Scientists. She also is the Visiting Professor at the School of Life Sciences and Technology, Tongji University Shanghai and the Adjunct Professor, Academy of Medical Sciences, Zhengzhou University, China.

Contact details:

Dr Belamy Cheung
Children's Cancer Institute Australia.
61 02 9385 2450

bcheung@ccia.unsw.edu.au

School:

Sch Women's&Children's Health

Phone:

(02) 9385 2450

Email:

bcheung@ccia.unsw.edu.au

University role:

Manager of the Molecular Carcinogenesis Program

Qualifications:

Academic and Professional Qualifications:

2004: Doctor of Philosophy, School of Women's and Children's Health, Medicine Faculty, University of New South Wales, Australia. (Awarded on 18/5/2004)
1994: Master of Science, School of Pathology, Medicine Faculty, University of New South Wales, Australia.
1983: Bachelor of Medicine, Sun Yat-Sen University of Medical Science, Guangzhou, P. R. China.

Grants:

Project Grant, Kids Cancer Alliance NSW, Application title “Prevention of Child Cancer – Down Syndrome”. Total of $160,000. $ 80,000/year for 2 years from 2018.
NHMRC Project Grant , Application title “Therapeutic targeting of MYCN oncoprotein stability in neuroblastoma”. $590,206.20. from 2017-2019.

UNSW Goldstar Award 2016, APP1101902, Proposal Title: Therapeutic targeting of the MYCN oncogenic signal in childhood neuroblastoma by inhibition of transcriptional elongation complex, FACT”, RG153043, $40,000

Project Grant, CCIA Drug Screening Fund, titled “Identification of novel compounds which enhance the retinoid anti-cancer signal using a high-content TRIM16 translocation assay”. 2012, $10,000

Project Grant, Faculty of Medicine, University of NSW, project title: “Overcoming histone deacetylase inhibitor and retinoid drug resistance through novel combination therapies”, 2011, $11,000

Early Career Development fellowship, ID: 06/ECF/1-04, Cancer Institute New South Wales, 2007-2009, $570, 000

Project grant, Cure Cancer Australia, 2007, $75, 000

Awards:

1. Australia Postgraduate Research Award, 1990-1992
2. Early Career Research Awards, Faculty of Medicine, UNSW, Sydney, 2005
3. Early Career Development fellowship Award, Cancer Institute NSW, 2007
4. The Institute Award for outstanding service, Children’s Cancer Institute Australia, 2010
5. Goldstar Award for a research project, UNSW Sydney, 2016
6. Travel grant, School of Life Sciences and Technology, Shanghai Tongji University, China. 2017.

Research

Research activities:

Current Research Projects:

1. Developing inhibitors for MYC oncoproteins.

2. Identification of co-factors for MYCN oncoprotein.

3. Establishing novel combination therapies of epigenetic drugs for cancer treatment.

Socio-economic Objective (SEO) tags:

Child Health

Field of Research (FOR) Tag:

Paediatrics

Teaching & Supervision

I am available to supervise:

Yes

Areas of supervision:

ILP, Honours, Masters, PhD

Supervision keywords:

breast cancer

skin cancer

experimental cancers

anticancer drugs

nervous system cancers

antineoplastics and immunosuppressives

Media

Facebook:

https://www.facebook.com/UNSWWomensChildrensHealth/

Publications related to this Person

Journal articles

Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT, 2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, vol. 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034

Tang Y; Cheung BB; Atmadibrata B; Marshall GM; Dinger ME; Liu PY; Liu T, 2017, 'The regulatory role of long noncoding RNAs in cancer', Cancer Letters, vol. 391, pp. 12 - 19, http://dx.doi.org/10.1016/j.canlet.2017.01.010

Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J, 2016, 'The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs', Oncotarget, vol. 7, pp. 79217 - 79232, http://dx.doi.org/10.18632/oncotarget.12640

Fabian J; Opitz D; Althoff K; Lodrini M; Hero B; Volland R; Beckers A; Preter KD; Decock A; Patil N, 2016, 'MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma', Oncotarget, vol. 7, pp. 66344 - 66359, http://dx.doi.org/10.18632/oncotarget.11662

Xue C; Yu DMT; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB, 2016, 'MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4', Oncotarget, vol. 7, pp. 54937 - 54951, http://dx.doi.org/10.18632/oncotarget.10709

Sutton SK; Carter DR; Kim P; Tan O; Arndt GM; Zhang XD; Baell J; Noll BD; Wang S; Kumar N, 2016, 'A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner', Oncotarget, vol. 7, pp. 52166 - 52178, http://dx.doi.org/10.18632/oncotarget.10700

Bingul M; Tan O; Gardner CR; Sutton SK; Arndt GM; Marshall GM; Cheung BB; Kumar N; Black DSC, 2016, 'Synthesis, characterization and anti-cancer activity of hydrazide derivatives incorporating a quinoline moiety', Molecules, vol. 21, http://dx.doi.org/10.3390/molecules21070916

Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD, 2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, vol. 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675

Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE, 2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, vol. 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004

Kim PY; Tan O; Liu B; Trahair T; Liu T; Haber M; Norris MD; Marshall GM; Cheung BB, 2016, 'High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients', Cancer Letters, vol. 374, pp. 315 - 323, http://dx.doi.org/10.1016/j.canlet.2016.02.021

Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G, 2015, 'Erratum: Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression (Journal of the National Cancer Institute (2014) 106:7 (dju113) DOI: 10.1093/jnci/dju113)', Journal of the National Cancer Institute, vol. 107, http://dx.doi.org/10.1093/jnci/dju359

Cheung BB, 2015, 'Combination therapies improve the anticancer activities of retinoids in neuroblastoma', World Journal of Clinical Oncology, vol. 6, pp. 212 - 215, http://dx.doi.org/10.5306/wjco.v6.i6.212

Carter DR; Murray J; Cheung BB; Gamble L; Koach J; Tsang J; Sutton S; Kalla H; Syed S; Gifford AJ, 2015, 'Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma', Science Translational Medicine, vol. 7, http://dx.doi.org/10.1126/scitranslmed.aab1803

Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M, 2015, 'Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: Implications for targeted treatment', Clinical Cancer Research, vol. 21, pp. 3327 - 3339, http://dx.doi.org/10.1158/1078-0432.CCR-14-2024

Beckers A; Van Peer G; Carter DR; Gartlgruber M; Herrmann C; Agarwal S; Helsmoortel HH; Althoff K; Molenaar JJ; Cheung BB, 2015, 'MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma', Cancer Letters, http://dx.doi.org/10.1016/j.canlet.2015.06.015

Beckers A; Peer GV; Carter DR; Mets E; Althoff K; Cheung BB; Schulte JH; Mestdagh P; Vandesompele J; Marshall GM, 2015, 'MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation', Oncotarget, vol. 6, pp. 5204 - 5216, http://dx.doi.org/10.18632/oncotarget.2477

Bingul M; Cheung BB; Kumar N; Black DSC, 2014, 'Synthesis of symmetrical and unsymmetrical diindolylmethanes via acid-catalysed electrophilic substitution reactions', Tetrahedron, vol. 70, pp. 7363 - 7369, http://dx.doi.org/10.1016/j.tet.2014.06.087

Sutton SK; Koach J; Tan O; Liu B; Carter DR; Wilmott JS; Yosufi B; Haydu LE; Mann GJ; Thompson JF, 2014, 'TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells', Oncotarget, vol. 5, pp. 10127 - 10139, http://dx.doi.org/10.18632/oncotarget.2466

Cheung BB; Tan O; Koach J; Liu B; Shum MSY; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M, 2014, 'Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma', Molecular Oncology, http://dx.doi.org/10.1016/j.molonc.2015.04.005

Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G, 2014, 'Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression', Journal of the National Cancer Institute, vol. 106, http://dx.doi.org/10.1093/jnci/dju113

Tee AE; Ling D; Nelson C; Atmadibrata B; Dinger ME; Xu N; Mizukami T; Liu PY; Liu B; Cheung B, 2014, 'The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1', Oncotarget, vol. 5, pp. 1793 - 1804, http://dx.doi.org/10.18632/oncotarget.1785

Marshall GM; Mateos MK; Carter DR; Cheung BB; Liu T; Meyerowitz JG; Weiss WA, 2014, 'The prenatal origins of cancer', Nature Reviews Cancer, http://dx.doi.org/10.1038/nrc3679

Kim PY; Tan O; Diakiw SM; Carter D; Sekerye EO; Wasinger VC; Liu T; Kavallaris M; Norris MD; Haber M, 2014, 'Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach', Journal of Proteomics, vol. 96, pp. 1 - 12, http://dx.doi.org/10.1016/j.jprot.2013.10.032

Kim PY; Rahmanto AS; Tan O; Norris MD; Haber M; Marshall GM; Cheung BB, 2013, 'TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells', Apoptosis, vol. 18, pp. 639 - 651, http://dx.doi.org/10.1007/s10495-013-0813-y

Bell JL; Malyukova A; Kavallaris M; Marshall GM; Cheung BB, 2013, 'TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization', Cell Cycle, vol. 12, pp. 889 - 898, http://dx.doi.org/10.4161/cc.23825

Liu PY; Xu N; Malyukova A; Scarlett CJ; Sun YT; Zhang XD; Ling D; Su SP; Nelson C; Chang DK, 2013, 'The histone deacetylase SIRT2 stabilizes Myc oncoproteins', Cell Death and Differentiation, vol. 20, pp. 503 - 514, http://dx.doi.org/10.1038/cdd.2012.147

Calao M; Sekyere EO; Cui HJ; Cheung BB; Thomas WD; Keating J; Chen JB; Raif A; Jankowski K; Davies NP, 2013, 'Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation', Oncogene, vol. 32, pp. 3616 - 3626, http://dx.doi.org/10.1038/onc.2012.368

Bell JL; Malyukova A; Holien JK; Koach J; Parker MW; Kavallaris M; Marshall GM; Cheung BB, 2012, 'TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0037470

Gardner CR; Cheung BB; Koach J; Black DS; Marshall GM; Kumar N, 2012, 'Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy', Bioorganic and Medicinal Chemistry, vol. 20, pp. 6877 - 6884, http://dx.doi.org/10.1016/j.bmc.2012.09.035

Cheung BB; Koach J; Tan O; Kim P; Bell JL; D'Andreti C; Sutton S; Malyukova A; Sekyere E; Norris M, 2012, 'The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro', Journal of Pathology, vol. 226, pp. 451 - 462, http://dx.doi.org/10.1002/path.2986

Cheung BB; Marshall GM, 2011, 'Targeting ATP7A to increase the sensitivity of neuroblastoma cells to retinoid therapy', Current Cancer Drug Targets, vol. 11, pp. 826 - 836, http://dx.doi.org/10.2174/156800911796798968

Marshall GM; Bell JL; Koach J; Tan O; Kim P; Malyukova A; Thomas W; Sekyere EO; Liu T; Cunningham AM, 2010, 'TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells', Oncogene, vol. 29, pp. 6172 - 6183, http://dx.doi.org/10.1038/onc.2010.340

Bohlken A; Cheung BB; Bell JL; Koach J; Smith S; Sekyere E; Thomas W; Norris M; Haber M; Lovejoy DB, 2009, 'ATP7A is a novel target of retinoic acid receptor β2 in neuroblastoma cells', British Journal of Cancer, vol. 100, pp. 96 - 105, http://dx.doi.org/10.1038/sj.bjc.6604833

Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B, 2009, 'Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression', Oncogene, vol. 28, pp. 1605 - 1615, http://dx.doi.org/10.1038/onc.2009.3

Raif A; Marshall GM; Bell JL; Koach J; Tan O; D'andreti C; Thomas W; Sekyere E; Norris M; Haber M, 2009, 'The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation', Cancer Letters, vol. 277, pp. 82 - 90, http://dx.doi.org/10.1016/j.canlet.2008.11.030

Cheung BB; Bell J; Raif A; Bohlken A; Yan J; Roediger B; Poljak A; Smith S; Lee M; Thomas WD, 2006, 'The estrogen-responsive B box protein is a novel regulator of the retinoid signal', Journal of Biological Chemistry, vol. 281, pp. 18246 - 18256, http://dx.doi.org/10.1074/jbc.M600879200

Liu T; Bohlken A; Kuljaca S; Lee M; Nguyen T; Smith S; Cheung B; Morris MD; Haber M; Holloway AJ, 2005, 'The retinoid anticancer signal: Mechanisms of target gene regulation', British Journal of Cancer, vol. 93, pp. 310 - 318, http://dx.doi.org/10.1038/sj.bjc.6602700

Nguyen T; Hocker JE; Thomas W; Smith SA; Norris MD; Haber M; Cheung B; Marshall GM, 2003, 'Combined RARα- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells', Biochemical and Biophysical Research Communications, vol. 302, pp. 462 - 468, http://dx.doi.org/10.1016/S0006-291X(03)00177-3

Hansford LM; Smith SA; Haber M; Norris MD; Cheung B; Marshall GM, 2003, 'Cloning and characterization of the human neural cell adhesion molecule, CNTN4 (alias BIG-2)', Cytogenetic and Genome Research, vol. 101, pp. 17 - 23, http://dx.doi.org/10.1159/000073412

Cheung B; Yan J; Smith SA; Nguyen T; Lee M; Kavallaris M; Norris MD; Haber M; Marshall GM, 2003, 'Growth inhibitory retinoid effects after recruitment of retinoid X receptor β to the retinoic acid receptor β promoter', International Journal of Cancer, vol. 105, pp. 856 - 867, http://dx.doi.org/10.1002/ijc.11153

Cheung B; Hocker JE; Smith SA; Norris MD; Haber M; Marshall GM, 1998, 'Favorable prognostic significance of high-level retinoic acid receptor β expression in neuroblastoma mediated by effects on cell cycle regulation', Oncogene, vol. 17, pp. 751 - 759, http://dx.doi.org/10.1038/sj.onc.1201982

Kavallaris M; Gardaneh M; Cheung B; Camacho ML; Hocker JE; Norris MD; Haber M; Marshall GM, 1998, 'In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells', Anticancer Research, vol. 18, pp. 1793 - 1797

Cheung B; Hocker JE; Smith SA; Reichert U; Norris MD; Haber M; Stewart BW; Marshall GM, 1996, 'Retinoic acid receptors β and γ distinguish retinoid signals for growth inhibition and neuritogenesis in human neuroblastoma cells', Biochemical and Biophysical Research Communications, vol. 229, pp. 349 - 354, http://dx.doi.org/10.1006/bbrc.1996.1804

Marshall GM; Cheung B; Stacey KP; Camacho ML; Simpson AM; Kwan E; Smith S; Haber M; Norris MD, 1995, 'Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells', Oncogene, vol. 11, pp. 485 - 491

Marshall GM; Cheung B; Stacey KP; Norris MD; Haber M, 1994, 'Regulation of retinoic acid receptor alpha expression in human neuroblastoma cell lines and tumor tissue', Anticancer Research, vol. 14, pp. 437 - 441

Haber M; Madafiglio J; Bordow SB; Gilbert J; Cheung B; Marshall GM; Norris MD, 1994, 'Expression of retinoic acid-responsive genes in primary neuroblastomas.', Progress in clinical and biological research, vol. 385, pp. 245 - 251

Marshall GM; Cheung B; Stacey KP; Norris MD; Haber M, 1994, 'Regulation of retinoic acid receptor alpha expression in human neuroblastoma cell lines and tumor tissue.', Anticancer Res, vol. 14, pp. 437 - 441, https://www.ncbi.nlm.nih.gov/pubmed/8017844

Bordow SB; Haber M; Madaflglio J; Cheung B; Marshall GM; Norris MD, 1994, 'Expression of the Multidrug Resistance-associated Protein (MRP) Gene Correlates with Amplification and Overexpression of the N-myc Oncogene in Childhood Neuroblastoma', Cancer Research, vol. 54, pp. 5036 - 5040

Conference Papers

Cheung BB; Sutton SK; Tan O; Koach J; Liu B; Liu T; Scolyer RA; Zhang XD; Marshall GM, 2013, 'TRIM16 is a prognostic marker for patients with lymph node metastatic melanoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-3876

Bell JL; Cheung BB; D'Andreti C; Koach J; Raif A; Thomas WD; Norris M; Haber M; Kavallaris M; Marshall GM, 2008, 'The role of the estrogen-responsive B box protein (EBBP) in cancer cell cycle progression', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Lyon, FRANCE, pp. 95 - 95, presented at 20th Meeting of the European-Association-for-Cancer-Research, Lyon, FRANCE, 05 - 08 July 2008, http://dx.doi.org/10.1016/S1359-6349(08)71542-8

Thomas W; Chen J; Gao Y; Koach J; Cheung B; Ellis T; Norris M; Haber M; Wainwright B; Marshall G, 2008, 'STABILIZATION OF THE MYCN ONCOPROTEIN AS A MECHANISM OF INITIATION AND PROGRESSION IN MEDULLOBLASTOMA RESULTING FROM SONIC HEDGEHOG PATHWAY ACTIVATION', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Las Vegas, NV, pp. 870 - 870, presented at 13th Annual Meeting of the Society-for-Neuro-Oncology (SNO), Las Vegas, NV, 20 - 23 November 2008, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259854500409&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cheung BB; Bell J; Raif A; Yan J; Roediger B; Smith S; Lee M; Thomas WD; Kavallaris M; Norris M, 2006, 'Characterization of a novel regulator of the retinoid signal: The estrogen-responsive B box protein.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454608804357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thomas WD; Keating J; Cheung B; Armatai P; Weiss W; Norris M; Haber M; Marshall GM, 2006, 'Neuroblastoma tumor initiation: MYCN mediated mechanisms of resistance to cell death', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454606201380&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Deubzer H; Fabian J; Opitz D; Althoff K; Lodrini M; Astrahantseff K; Hero B; Volland R; Beckers A; De Preter K, 2015, 'MYCN TRANSCRIPTIONALLY REPRESSES CD9 TO TRIGGER AN INVASION-METASTASIS CASCADE IN NEUROBLASTOMA', in PEDIATRIC BLOOD & CANCER, WILEY-BLACKWELL, Vol. 62, pp. S150 - S150, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361247200022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

School of Women's and Children's Health

Dr Belamy-Bin Cheung

Tabs

Study @ WCH

Research @ WCH

Quick Links

Connect